Rapport Therapeutics Reports Updated Phase 2a Data for Seizure Drug RAP-219

Rapport Therapeutics has released updated Phase 2a data for its investigational seizure drug RAP-219, showing a 77.8% median reduction in clinical seizures over 8 weeks in patients with drug-resistant focal onset seizures 235.

In the same Phase 2a trial, 24% of patients achieved seizure freedom during the 8-week treatment period, and the drug demonstrated consistent efficacy in both the first and second halves of treatment 235.

Post-hoc analyses show that RAP-219’s effect was consistent regardless of baseline disease severity and that patients with moderate or greater baseline impairment reported meaningful improvements in seizure severity and daily functioning 23.

RAP-219 was generally well tolerated; the company plans an end-of-Phase 2 meeting with the U.S. FDA in late 2025 and expects to start two pivotal Phase 3 trials in the third quarter of 2026 35.

The Phase 2a trial enrolled 30 patients with drug-resistant focal onset seizures who had an implanted responsive neurostimulation (RNS) system, and RAP-219 met its primary endpoint of reducing long episodes (a biomarker for clinical seizures) with high statistical significance 345.

Sources:

2. https://www.investing.com/news/company-news/rapports-epilepsy-drug-shows-early-efficacy-in-phase-2a-trial-93CH-4393636

3. https://www.globenewswire.com/news-release/2025/12/05/3200745/0/en/Rapport-Therapeutics-Announces-New-Data-and-Post-Hoc-Analysis-Demonstrating-the-Magnitude-and-Consistency-of-RAP-219-s-Clinical-Response-in-Patients-with-Focal-Onset-Seizures.html

4. https://www.tabletscapsules.com/3639-News/621270-Rapport-Seizure-Drug-Shines-in-Phase-2-Trial/

5. https://www.neurologylive.com/view/rap-219-meets-primary-end-point-phase-2a-trial-focal-onset-seizures